- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05856240
Targeted Group-based Psychotherapy to Address Emotional Stress in at Risk ICU Survivors
May 3, 2023 updated by: Katherine Berg, Beth Israel Deaconess Medical Center
Targeted Group-based Psychotherapy to Address Emotional Stress in at Risk ICU Survivors: A Pilot Feasibility Study
This study is a pilot clinical trial to assess the feasibility of implementing a group-psychotherapy intervention to modify emotional stress (e.g., anxiety, depression, post-traumatic stress) following ICU hospitalization
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Detailed Description
Psychological symptoms and emotional distress, including anxiety, depression, and posttraumatic stress, are common problems among patients discharged from the intensive care unit (ICU).
The presence of psychological distress is associated with poor medical adherence, slower recovery, and reduced quality of life in this patient population.
There is a lack of research on evidence-based interventions to address mental health symptoms in ICU patients post-hospitalization. Researchers have recently highlighted the potential utility of peer support/group interventions in the post-ICU recovery process; however, they have yet to be widely tested in interventional trials, and their feasibility and acceptability in the post-ICU population have yet to be demonstrated in a research study.
Thus, the purpose of this study is to adapt and deliver a 6-session group-based psychological intervention for post-ICU patients in a single-arm, non-randomized interventional study.
Patients' symptoms will be assessed at baseline, post-intervention, and 3-month follow-up.
The primary aim of the study is to assess the feasibility and acceptability of the group intervention in the post-ICU patient population.
Secondarily, changes in patients' emotional distress will be examined to assess for the impact of the intervention on patients' symptoms.
Study Type
Interventional
Enrollment (Anticipated)
34
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Katherine Berg, MD
- Phone Number: 617-754-2881
- Email: kberg@bidmc.harvard.edu
Study Contact Backup
- Name: Jolin Yamin, PhD
- Email: jyamin@bidmc.harvard.edu
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Aged at least 18 years
- ICU stay of at least 3 days
- Access to a smartphone, laptop, or computer and able to participate in a meeting via a virtual platform
- Montreal Cognitive Assessment (MoCA)-BLIND score of at least 18
- English fluency
- Screening questionnaires consistent with clinically significant depression OR anxiety (Hospital Anxiety and Depression Scale-Depression [HADS-D] OR HADS-Anxiety [HADS- A] score of >7) OR Post-traumatic Stress (PTSD Checklist-Civilian Version [PCL-C] score of ≥ 30)
- Resides in the state of Massachusetts.
Exclusion Criteria:
- Unable or unwilling to participate in 6 weekly sessions of group therapy
- Permanent or severe cognitive impairment severe enough to impede participation (as assessed via the MMSE).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group-Based Psychological Intervention
Single-arm feasibility trial, so all participants will receive the intervention.
|
The intervention consists of 6, 90-minute weekly sessions and includes the following components: providing education about psychological and emotional reactions to stress, introducing and practicing coping skills (e.g., mindfulness, emotional awareness, flexible thinking, behavioral modification), decreasing psychological avoidance using emotional exposure, and facilitating group support and discussion (see De Paul & Caver, 2021 for original protocol description).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility of recruitment
Time Frame: Baseline
|
This will be determined by reporting the number of patients who meet study criteria who agreed to participate.
|
Baseline
|
Adherence to sessions (acceptability)
Time Frame: At 6 weeks (immediately at end of intervention sessions)
|
This will be determined by reporting the number of intervention sessions completed by each participant.
|
At 6 weeks (immediately at end of intervention sessions)
|
Feasibility of data collection at post-treatment
Time Frame: At 6 weeks (immediately at end of intervention sessions)
|
This will be determined by reporting the number of participants who provide post-treatment data.
|
At 6 weeks (immediately at end of intervention sessions)
|
Feasibility of data collection at follow-up
Time Frame: At 3 months follow-up
|
This will be determined by reporting the number of participants who provide follow-up data.
|
At 3 months follow-up
|
Client Satisfaction Questionnaire
Time Frame: At 6 weeks (immediately at end of intervention sessions)
|
This measure assesses participants' satisfaction with the intervention (participant ratings of 1 to 4, higher scores indicate higher satisfaction).
|
At 6 weeks (immediately at end of intervention sessions)
|
Credibility and Expectancy Questionnaire
Time Frame: Baseline
|
This measure assesses participants' expectations and beliefs that the intervention will be helpful (Participant ratings of 1 to 9, higher scores indicate higher beliefs that the intervention will be helpful).
|
Baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29)- Anxiety
Time Frame: Change from Baseline to immediately Post-Intervention (at 6 weeks), and from Baseline to to 3-months Follow-up
|
This sub-scale of the PROMIS measure assesses participants' anxiety symptoms (Participant ratings of 1 to 5, higher ratings indicate greater anxiety symptoms).
|
Change from Baseline to immediately Post-Intervention (at 6 weeks), and from Baseline to to 3-months Follow-up
|
Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29)- Depression
Time Frame: Change from Baseline to immediately Post-Intervention (at 6 weeks), and from Baseline to to 3-months Follow-up
|
This sub-scale of the PROMIS measure assesses participants' depression symptoms (Participant ratings of 1 to 5, higher ratings indicate greater depression symptoms).
|
Change from Baseline to immediately Post-Intervention (at 6 weeks), and from Baseline to to 3-months Follow-up
|
PTSD Checklist-Civilian Version (PCL-C)
Time Frame: Change from Baseline to immediately Post-Intervention (at 6 weeks), and from Baseline to to 3-months Follow-up
|
This measure assesses participants' PTSD symptoms (Participant ratings of 1 to 5, higher ratings indicate greater PTSD symptoms).
|
Change from Baseline to immediately Post-Intervention (at 6 weeks), and from Baseline to to 3-months Follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Katherine M Berg, MD, Beth Israel Deaconess Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
May 1, 2023
Primary Completion (Anticipated)
December 1, 2023
Study Completion (Anticipated)
March 1, 2024
Study Registration Dates
First Submitted
April 24, 2023
First Submitted That Met QC Criteria
May 3, 2023
First Posted (Actual)
May 12, 2023
Study Record Updates
Last Update Posted (Actual)
May 12, 2023
Last Update Submitted That Met QC Criteria
May 3, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023P000087
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Lawson Health Research InstituteTerminated
Clinical Trials on Managing Stress & Emotions Group (MSEG)
-
King's College LondonSouth London and Maudsley NHS Foundation TrustCompletedSevere Mental IllnessUnited Kingdom
-
Stanford UniversityRecruiting
-
VA Palo Alto Health Care SystemCompleted
-
Wayne State UniversityUniversity of Michigan; St. John Providence HospitalCompleted
-
Massachusetts General HospitalNational Center for Complementary and Integrative Health (NCCIH)CompletedStress, Psychological | Stress, PhysiologicalUnited States
-
Massachusetts General HospitalThe Children's Tumor FoundationCompletedNeurofibromatosis 2United States
-
Massachusetts General HospitalThe Children's Tumor FoundationCompletedNeurofibromatosesUnited States
-
Susana Nunez NagyUniversity of Alcala; Universidad Complutense de Madrid; European University... and other collaboratorsCompletedStress, PsychologicalFrance, Spain
-
Gazi UniversityCompletedStress | Anxiety | Depressive SymptomsTurkey
-
Saglik Bilimleri Universitesi Gulhane Tip FakultesiCompletedPain | Anxiety | Satisfaction